buyWeak cluster of 2
Charles Theuer bought $7,600 of TCON
President and CEO at Tracon Pharmaceuticals, Inc.. 5,000 shares at an average of $1.52, traded Feb 28, 2023, filed Mar 2, 2023.
Conviction score
38Value
$7,600
5,000 shares
Holdings after
344,918
+1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- 0Trade size$8k at market
- 0Relative to holdingsHoldings up 1.5%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-014434, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 28, 2023 | POpen-market purchase Common Stock | +200 | $1.52 | $304 | 340,118 | Mar 2, 2023 |
| Mar 1, 2023 | POpen-market purchase Common Stock | +4,800 | $1.52 | $7,296 | 344,918 | Mar 2, 2023 |
Related signals
Other insiders at Tracon Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | TCONsell Tracon Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.4M 4,764,008 shares | -110% | |
| 39Weak | TCONbuy Tracon Pharmaceuticals, Inc. | Charles Theuer President and CEO | $38k 50,999 shares | +15% | |
| 43Moderate | Tracon Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $241k 174,508 shares | +4% | |
| 15Weak | TCONsell Tracon Pharmaceuticals, Inc. | William R Larue director | $151 120 shares | -2% | |
| 30Weak | TCONbuy Tracon Pharmaceuticals, Inc. | Charles Theuer President and CEO | $11k 6,800 shares | +2% | |
| 25Weak | TCONbuy Tracon Pharmaceuticals, Inc. | Scott B. Brown Chief Financial Officer | $5,215 3,500 shares | +19% | |
| 42Moderate | Tracon Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $210k 167,500 shares | +4% | |
| 46Moderate | Tracon Pharmaceuticals, Inc. | Charles Theuer President and CEO | $30k 23,000 shares | +7% | |
| 12Weak | TCONsell Tracon Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $2,216 1,539 shares | -0% | |
| 30Weak | TCONbuy Tracon Pharmaceuticals, Inc. | Charles Theuer President and CEO | $20k 13,900 shares | +5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.